Cochrane review: Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma.

OBJECTIVES:

To assess the effectiveness and toxicity of short versus long infusions of paclitaxel for any advanced adenocarcinoma.

"Adverse events were not comprehensively reported for any of the other comparisons. Outcomes were incompletely documented and QoL outcomes were not reported in any of the trials. The strength of the evidence is weak in this review as it is based on meta analyses of very few trials or single trial analyses and all trials were at moderate risk of bias and two were published in abstract form only."